Form 4 for NVCR NovoCure Ltd
Accepted 2022-03-07 00:00:00 ET · period of report 2022-03-03 · accession 0001645113-22-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-07 | 2022-03-03 | NVCR | Shah Pritesh | Chief Commercial Off | A - Grant | $0.00 | +21.7K | 95.2K | +30% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $72.54 | -5,543 | 89.7K | -6% | -$402.1K |
| DM | 2022-03-07 | 2022-03-03 | NVCR | Shah Pritesh | Chief Commercial Off | A - Grant | $80.59 | +44.3K | 6,231 | New | +$3.57M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-03-03 | A | A | 21,714 | $0.00 | 95,226 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. |
| 2 | Common | Ordinary Shares | 2022-03-03 | S | D | 997 | $74.50 | 94,229 | D | — | — | (F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 3 | Common | Ordinary Shares | 2022-03-04 | S | D | 2,632 | $73.34 | 91,597 | D | — | — | (F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 4 | Common | Ordinary Shares | 2022-03-04 | S | D | 1,914 | $70.41 | 89,683 | D | — | — | (F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 5 | Derivative | Options to Buy Ordinary Shares | 2022-03-03 | A | A | 38,027 | $80.59 | 38,027 | D | $80.59 · 2023-03-01 to 2032-02-29 | 38,027 Ordinary Shares | (F3) Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. |
| 6 | Derivative | Options to Buy Ordinary Shares | 2022-03-03 | A | A | 6,231 | $80.59 | 6,231 | D | $80.59 · 2023-03-01 to 2032-02-29 | 6,231 Ordinary Shares | (F4) Options to buy 6,231 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. |